UPM Institutional Repository

Critical roles of IL-33/ST2 pathway in neurological disorders


Abd Rachman Isnadi, Mohammad Faruq and Chin, Voon Kin and Abd. Majid, Roslaini and Lee, Tze Yan and Abdullah, Maizaton Atmadini and Omenesa, Ramatu Bello and Ibraheem, Zaid Osamah and Basir, Rusliza (2018) Critical roles of IL-33/ST2 pathway in neurological disorders. Mediators of Inflammation, 2018. art. no. 5346413. pp. 1-9. ISSN 0962-9351; ESSN: 1466-1861


Interleukin-33 (IL-33) is an IL-1 family member, which exhibits both pro- and anti-inflammatory properties solely based on the type of the disease itself. Generally, IL-33 is expressed by both endothelial and epithelial cells and mediates its function based on the interaction with various receptors, mainly with ST2 variants. IL-33 is a potent inducer for the Th2 immune response which includes defence mechanism in brain diseases. Thus, in this paper, we review the biological features of IL-33 and the critical roles of IL-33/ST2 pathway in selected neurological disorders including Alzheimer’s disease, multiple sclerosis, and malaria infection to discuss the involvement of IL-33/ST2 pathway during these brain diseases and its potential as future immunotherapeutic agents or for intervention purposes.

Download File

[img] Text
neurological disorders.pdf
Restricted to Repository staff only

Download (2MB)
Official URL or Download Paper: https://www.hindawi.com/journals/mi/2018/5346413/

Additional Metadata

Item Type: Article
Divisions: Faculty of Medicine and Health Science
DOI Number: https://doi.org/10.1155/2018/5346413
Publisher: Hindawi
Keywords: Interleukin-33; IL-33/ST2; Neurological disorders; Alzheimer’s disease; Multiple sclerosis; Malaria infection
Depositing User: Nurul Ainie Mokhtar
Date Deposited: 04 Mar 2020 04:03
Last Modified: 04 Mar 2020 04:03
Altmetrics: http://www.altmetric.com/details.php?domain=psasir.upm.edu.my&doi=10.1155/2018/5346413
URI: http://psasir.upm.edu.my/id/eprint/72141
Statistic Details: View Download Statistic

Actions (login required)

View Item View Item